

Investing in companies of the future: A unique, well-defined process of investing in biotechnology and life sciences companies.



The Next Edge Biotech and Life Sciences Opportunities Fund (the 'Fund') seeks short and long-term capital appreciation through the ownership of biotechnology and life sciences companies. Investments by the Fund may be made globally.



Investing in companies of the future: A unique, well-defined process of investing in biotechnology and life sciences companies.

Why Invest in Biotech and Life Sciences?

Accelerated discoveries, as technology has fused with biotech.

Higher Success Rates on discoveries due to innovation from research and development progress.

Vast Wealth Creation potential due to rapidly increasing breakthroughs from the companies of tomorrow.

Accommodating regulatory environment.

Life-Saving and Quality of Life Solutions are being created for all humankind by investing in the sector.

Why Invest in the Next Edge Biotech and Life Sciences Opportunities Fund?

- Access to companies that have the potential to be tomorrow's winners.
- Experienced management team with over two decades of experience in biotech and life sciences.
- A unique, well-defined investment process of investing in companies in this sector.
- Specialized knowledge and experience required to navigate and invest in this space.
- The Fund's Portfolio Manager has a robust prior track record via other funds managed in biotech and healthcare.
- The Fund's Portfolio Management team have a vast network of contacts within investible companies, key opinion leaders (KOL), research firms, and other information sources globally.
- Only dedicated fund in Canada with exposure to predominately small and midcap Biotech and Life Sciences companies.

FUND DETAILS

Manager	Next Edge Capital Corp.
Fund Type	Alternative Mutual Fund
Launch Date	January 2023
Registered Plan Status	Eligible
Minimum Initial Investment	\$5,000
Minimum Subsequent Investment	\$1,000
Redemptions / Purchases	Daily
Management Fee (Includes Servicing Fee)	Class A: 1.5% (1% Servicing Fee payable out of the Management Fee) Class F: 0.5%
Performance Fee	20% of profits with a high water mark
Valuation Pricing	Daily
Auditor	Deloitte LLP
Registrar, Administrator and Valuation Agent	RBC Investor Services Trust
Custodian	RBC Investor Services Trust
Fund Code	Class A - NEC 226 Class F - NEC 227

INVESTMENT MANAGEMENT TEAM



EDEN RAHIM
Portfolio Manager

Eden Rahim is the Portfolio Manager for the Next Edge Biotech and Life Sciences Opportunities Fund. He also manages the Purpose Healthcare Innovation Yield ETF (TSX ticker: HEAL) as a sub-advisor. Eden's broad experience includes over twenty-five

years as a Portfolio and Hedge Fund Money Manager, Options Strategist, Derivatives & Biotech Analyst.

Eden possesses a top quartile 5-year 5-Star growth fund Portfolio Manager track record on over \$1 billion in assets across 4 mandates at RBC Global Asset Management, in addition, Eden has delivered a +26% compounded annual return across a biotechnology mandate between 1995-2003. His experience also includes overseeing 14 Covered Call ETFs (over \$0.7 Billion AUM) in Canada, the US, & Australia while at Horizons Exchange Traded Funds.

Eden is a regular guest speaker on the biotech industry on Bloomberg TV, BNN, as well as an author and contributor to many industry sources and major press articles in the US and Canada. He also contributes as a speaker at numerous healthcare conferences.



MICHAEL BIRD
Associate Portfolio Manager

Michael Bird is the Associate Portfolio Manager and Trader for the Next Edge Biotech and Life Sciences Opportunities Fund.

He possesses over twenty-five years of equity, options, and derivatives trading experience. Previously he

was Vice President and Head of the equity derivatives group at Desjardins Securities. Other prior experience includes Vice President and Senior Trader in the equity derivatives group at RBC, Vice President at CIBC Wood Gundy, and options and proprietary trader at BNS.

Mike has served on the TSE Derivative Markets Committee and is a former Director and Chair of the Audit Committee of Intrinsic Technologies Corporation (TSX: ITC) in addition to other board experience.

IMPORTANT NOTES

The "Next Edge Biotech and Life Sciences Opportunities Fund" or "Fund" means the "Next Edge Biotech and Life Sciences Opportunities Fund". Capitalized terms not defined in this presentation are defined as set forth in the prospectus of the Fund (the "Prospectus"). This communication is not, and under no circumstances is to be construed as an invitation to make an investment in the Fund nor does it constitute a public offering to sell the Fund or any other products described herein. Applications for the Fund will only be considered on the terms of the Prospectus. Each purchaser of the units (the "Units") may have statutory or contractual rights of action under certain circumstances as disclosed in the Prospectus. Please review the provisions of the applicable securities legislation for particulars of these rights.

Terms defined herein shall have the same meaning as in the Prospectus. Potential investors should note that alternative investments can involve significant risks and the value of an investment may go down as well as up. There is no guarantee of trading performance and past or projected performance is not indicative of future results. Investors should review the Prospectus in its entirety for a complete description of the Fund, its risks, and consult their registered dealers before making an investment.

The information contained in this material is subject to change without notice and Next Edge Capital Corp. will not be held liable for any inaccuracies or misprints. The Fund has not been and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States. The Fund may not be offered or sold in the United States or to US persons.

Any descriptions or information involving investment process or strategies is provided for illustration purposes only, may not be fully indicative of any present or future investments, may be changed at the discretion of the Portfolio Manager, and are not intended to reflect performance. The following does not purport to be a complete summary of all of the risks associated with an investment in the Fund. Please see the Fund's Prospectus for a complete listing and description of the risks associated with an investment in the Fund. The Fund is generally exposed to the following risks: Biotechnology Industry Risk; Borrowing Risk; Counterparty Risk; Credit Risk; Cybersecurity Risk; Derivatives Risk; Equity Securities Risk; ETF Risk; Foreign Currency Risk; Foreign Securities Risk; Interest Rate Risk; Legislation and Litigation Risk; Leverage Risk; Liquidity Risk; Multiple Class Risk; Options Risk; Price Volatility Risk; Repurchase and Reverse Repurchase Transactions and Securities Lending Risk; Short Selling Risk; Stock Market Risk; Substantial Securityholder Risk and Tax Risk.

PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS

For Existing Investors and Investment Professional Use Only.